NCT04937907View on ClinicalTrials.gov

Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Alport Syndrome, X-Linked
Interventions
DRUG

Hydroxychloroquine Sulfate 100 milligram (mg) Tab

Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.

DRUG

Benazepril hydrochloride 10 milligram (mg) Tab

Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.

Trial Locations (1)

200062

RECRUITING

Shanghai Children's Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Children's Hospital

OTHER